Differential modulation by interferon γ of the sensitivity of human melanoma cells to cytolytic T cell clones that recognize differentiation or progression antigens

Cancer Immunology Immunotherapy

Volumn 42, Issue 4, 1996, Pages 203-212

  Kirkin, Alexei F ^a   Straten, Per Thor ^a   Zeuthen, Jesper ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

cytolytic T cell clones; immunogenicity; interferon ; interleukin 10; melanoma; melanoma associated antigens

Indexed keywords

DIFFERENTIATION ANTIGEN; MELANOMA ANTIGEN; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 4; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR ANTIGEN;

ARTICLE; CELL CLONE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNOGENICITY; MELANOMA CELL; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; ANTIGENS, CD; BASE SEQUENCE; DISEASE PROGRESSION; DOWN-REGULATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA, RECOMBINANT; INTERLEUKIN-10; LYMPHOKINES; MALE; MELANOMA; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; T-LYMPHOCYTES, CYTOTOXIC; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 8944263300     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050272     Document Type: Article

References (42)

1. Anichini A, Mortarini R, Parmiani G (1993) The role of cytokines in the modulation of cell surface antigens of human melanoma. Int J Biol Markers 8:151
2. Bakker ABH, Schreurs MWJ, Boer AJ de, Kawakami Y, Rosenberg SA, Adema GJ, Figdor CG (1994) Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 179:1005
3. Boël P, Wildmann C, Sensi ML, Brasseur R, Renauld J-C, Coulie P, Boon T, Van der Bruggen P (1995) BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2:167
4. Brasseur F, Rimoldi D, Lienard D, Lethe B, Carrel S, Arienti F, Suter L, Vanwijck R, Bourlond A, Humblet Y, Vacca A, Conese M, Lahaye T, Degiovanni G, Deraemaecker R, Beauduin M, Sastre X, Salamon E, Dreno B, Jager E, Knuth A, Chevreau C, Suciu S, Lachapelle JM, Pouillart P, Parmiani G, Lejeune F, Cerottini JC, Boon T, Marchand M (1995) Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 63:375
5. Brichard V, Van Pel A, Wölfel T, Wölfel C, De Plaen E, Lethé B, Coulie P, Boon T (1993) The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 178:489
6. Coulie PG, Brichard V, Van Pel A, Wölfel T, Schneider J, Traversari C, Mattei S, De Plaën E, Lurquin C, Szikora J-P, Renauld J-C, Boon T (1994) A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 180:35
7. Coulie PG, Lehmann F, Lethe B, Herman J, Lurquin C, Andrawiss M, Boon T (1995) A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci USA 92:7976
8. Creagan ET, Ahmann DL, Long HJ, Frytak S, Sherwin SA, Chang MN (1987) Phase II study of recombinant interferon-gamma in patients with disseminated malignant melanoma. Cancer Treat Rep 71:8439
9. Garbe C, Krasagakis K (1993) Effects of interferons and cytokines on melanoma cells. J Invest Dermatol. 100:239S
10. Gaugler B, Van den Eynde B, Van der Bruggen P, Romero P, Gaforio JJ, De Olaen E, Lethé B, Brasseur F, Boon T (1994) Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 179:921
11. Hellström KE, Hellström I (1991) Principles of tumor immunity: tumor antigens. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Biologic therapy of cancer. Lippincott, Philadelphia, p 35
12. Houghton AN, Herlyn M, Ferrone S. (1992) Melanoma antigens. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong S-J (eds) Cutaneous melanoma. Lippincott, Philadelphia, p 130
13. Ishihara K, Hayasaka K, Yamazaki N (1989) Current status of melanoma treatment with interferon cytokines and other biologic response modifiers in Japan. J Invest Dermatol 92:326S
14. Johnston RF, Pickett SC, Barker DL (1990) Autoradiography using storage phosphor technology. Electrophoresis 11:355
15. Kawakami Y, Eliyahu S, Delgado CH, Robbins PH, Sakaguchi K, Appella E, Yannelli JH, Adema GH, Miki T, Rosenberg SA (1994) Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 91:6458
16. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA (1994) Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 91:3515
17. Kirkin AF, Petersen TR, Olsen AC, Li L, thor Straten P, Zeuthen J (1995) Generation of human-melanoma-specific T lymphocyte clones defining novel cytolytic targets with panels of newly established melanoma cell lines. Cancer Immunol Immunother 41:71
18. Krasagakis K, Garbe C, Kruger S, Orfanos CE (1991) Effects of interferons on cultured human melanocytes in vitro: interferon-β but not -α or -γ inhibit proliferation and all interferons significantly modulate the cell phenotype. J Invest Dermatol 97:364
19. Lollini PL, De Giovanni C, Del Re B, Nicoletti G, Prodi G, Nanni P (1987) Interferon-mediated enhancement of metastasis. Are MHC antigens involved? Clin Exp Metastasis 5:277
20. Matsuda M, Salazar F, Petersson M, Masucci G, Hansson J, Pisa P, Zhang QJ, Masucci MG, Kiessling R (1994) Interleukin 10 pretreatment protects target cells from tumor-and allo-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med 180:2371
21. McMillan TJ, Rao J, Everett CA, Hart IR (1987) Interferon-induced alterations in metastatic capacity, class I antigen expression and natural killer cell sensitivity of melanoma cells. Int J Cancer 40:659
22. Meyskens FL Jr, Kopecky K, Samson M, Hersh E, MacDonald J, Jaffe H, Crowley J, Coltman C (1990) Recombinant human interferon gamma: adverse effects in high-risk stage I and II cutaneous melanoma (letter). J Natl Cancer Inst 82:1071
23. Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR (1993) Interleukin-10. Annu Rev Immunol 11:165
24. Mosmann TR, Coffman RL (1989) Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7:145
25. Olsen AC, Fossum B, Kirkin AF, Zeuthen J, Gaudernack G (1995) A human melanoma cell line, recognized by both HLA class I and class II restricted T cells, is capable of initiating both primary and secondary immune responses. Scand J Immunol 41:357
26. Prehn RT (1994) Stimulatory effects of immune reactions upon the growth of untransplanted tumors. Cancer Res 54:908
27. Prehn RT, Main JM (1957) Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 18:769
28. ser-interferon with gamma-interferons on human cell lines of various histogenesis. Cancer Res 46:483
29. Sensi M, Traversari C, Radrizzani M, Salvi S, Maccalli C, Mortarini R, Rivoltini L, Farina C, Nicolini G, Wölfel T, Brichard V, Boon T, Bordignon C, Anichini A, Parmiani G (1995) Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1. Proc Natl Acad Sci USA 92:5674
30. Stötter H, Wiebke EA, Tomita S, Belldegrun A, Topalian S, Rosenberg SA, Lotze MT (1989) Cytokines alter target cell susceptibility to lysis. II. Evaluation of tumor infiltrating lymphocytes. J Immunol 142:1767
31. Schwartzentruber DJ, Topalian SL, Manchini M, Rosenberg SA (1991) Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-α, and IFN-γ by human tumor-infiltrating lymphocytes after autologous tumor stimulation. J Immunol 146:3674
32. Trinchieri G, Perussia B (1985) Immune interferon: a pleiotropic lymphokine with multiple effects. Immunol Today 6:131
33. Trotta PP, Harrison SD Jr (1987) Evaluation of the antitumor activity of recombinant human gamma-interferon employing human melanoma xenografts in athymic nude mice. Cancer Res 47:5347
34. Van den Eynde B, Hainaut P, Hérin M, Knuth A, Lemoine C, Weynants P, Van der Bruggen B, Fauchet R, Boon T (1989) Presence on a human melanoma of multiple antigens recognized by autologous CTL. Int J Cancer 44:634
35. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T (1995) A new family of genes coding for an antigen recognized by autologous cytotoxic T lymphocytes on a human melanoma. J Exp Med 182:689
36. Van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643
37. Vánky F, Wang P, Patarroyo M, Klein E (1990) Expression of the adhesion molecule ICAM-1 and major histocompatibility complex class I antigens on human tumor cells is required for their interaction with autologous lymphocytes in vitro. Cancer Immunol Immunother 31:19
38. Wang R, Taniguchi M (1995) Limited T cell antigen receptor repertoire in umor-infiltrating lymphocytes and inhibition of experimental lung metastasis of murine melanoma by anti-TCR antibody. J Immunol 154:1797
39. Wang RF, Robbins PF, Kawakami Y, Kang XQ, Rosenberg SA (1995) Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med 181:799
40. Wiebke EA, Custer MC, Rosenberg SA, Lotze MT (1990) Cytokines alter target cell susceptibility to lysis. I. Evaluation of non-major histocompatibility complex-restricted effectors reveals different effects on natural and lymphokine-activated killing. J Biol Response Mod 9:113
41. Wölfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Büschenfelde HM zum, Boon T (1994) Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 24:759
42. INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281